IRIS
NATOLI, Clara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.424
EU - Europa 5.769
AS - Asia 4.085
SA - Sud America 462
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 5
Totale 17.801
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.361
SG - Singapore 1.596
CN - Cina 1.414
IE - Irlanda 1.016
UA - Ucraina 906
IT - Italia 785
SE - Svezia 774
FR - Francia 702
TR - Turchia 623
GB - Regno Unito 583
DE - Germania 453
BR - Brasile 414
IN - India 215
FI - Finlandia 164
RU - Federazione Russa 141
VN - Vietnam 92
AT - Austria 59
BE - Belgio 49
CA - Canada 39
HK - Hong Kong 38
CZ - Repubblica Ceca 30
PL - Polonia 24
BD - Bangladesh 18
EU - Europa 17
NL - Olanda 17
JP - Giappone 13
MX - Messico 13
AR - Argentina 12
ES - Italia 12
RO - Romania 11
IQ - Iraq 10
IL - Israele 9
UZ - Uzbekistan 9
EG - Egitto 8
LT - Lituania 8
MA - Marocco 7
UY - Uruguay 7
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
EC - Ecuador 6
PK - Pakistan 6
AL - Albania 5
AU - Australia 5
ID - Indonesia 5
SA - Arabia Saudita 5
ZA - Sudafrica 5
BO - Bolivia 4
CH - Svizzera 4
CO - Colombia 4
DK - Danimarca 4
DZ - Algeria 4
GR - Grecia 4
SN - Senegal 4
BG - Bulgaria 3
CL - Cile 3
HR - Croazia 3
JO - Giordania 3
KE - Kenya 3
KG - Kirghizistan 3
MT - Malta 3
PY - Paraguay 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AZ - Azerbaigian 2
DO - Repubblica Dominicana 2
IR - Iran 2
JM - Giamaica 2
LB - Libano 2
NI - Nicaragua 2
NP - Nepal 2
PE - Perù 2
PH - Filippine 2
PT - Portogallo 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
EE - Estonia 1
ET - Etiopia 1
HN - Honduras 1
HU - Ungheria 1
KW - Kuwait 1
LU - Lussemburgo 1
MK - Macedonia 1
NG - Nigeria 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
Totale 17.801
Salva come PNG Salva come JPEG
Città #
Chandler 1.479
Jacksonville 1.167
Singapore 1.143
Dublin 1.007
Princeton 466
Southend 414
Izmir 376
Nanjing 342
Beijing 315
Ashburn 301
Wilmington 224
The Dalles 195
Dearborn 189
Ann Arbor 177
Cambridge 174
Altamura 167
Santa Clara 162
Boardman 148
Chieti 138
Nanchang 125
Tongling 111
Los Angeles 108
Munich 103
Woodbridge 93
New York 91
Houston 80
Dong Ket 68
Shenyang 63
Hebei 60
Kunming 54
Tianjin 51
Brussels 47
Council Bluffs 47
Vienna 43
Washington 43
São Paulo 42
Jiaxing 40
Norwalk 37
Hong Kong 36
Rome 36
Nuremberg 34
Pescara 29
Brooklyn 28
Chicago 27
Helsinki 26
Hyderabad 26
Changsha 23
Seattle 23
Boston 22
Brno 22
Falls Church 22
Hangzhou 20
Hefei 20
Milan 20
Kocaeli 19
London 19
San Mateo 17
Lanzhou 16
Rio de Janeiro 15
San Francisco 15
Turku 15
Auburn Hills 14
Stockholm 14
Tappahannock 14
Warsaw 14
Augusta 13
Belo Horizonte 13
Changchun 13
Guangzhou 13
Düsseldorf 12
Frankfurt am Main 12
Grevenbroich 12
Shanghai 12
Tokyo 12
Toronto 12
Atlanta 11
Ningbo 11
Dallas 10
Edinburgh 10
Frontone 10
Mumbai 10
Campinas 9
Jinan 9
Leawood 9
Tashkent 9
Zhengzhou 9
Cairo 8
Fairfield 8
Giaveno 8
Ho Chi Minh City 8
Montreal 8
Moscow 8
Aprilia 7
Chennai 7
Phoenix 7
Pune 7
Amsterdam 6
Charlotte 6
Collecorvino 6
Denver 6
Totale 10.807
Salva come PNG Salva come JPEG
Nome #
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 152
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer 151
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 131
A multidisciplinary group for prostate cancer management: A single institution experience 130
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 128
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 127
New Targets for Therapy in Pancreatic Cancer 123
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 121
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 120
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 119
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 119
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patients survival. 118
45: L’UTILIZZO DELL’IMMUNOTERAPIA PER IL TRATTAMENTO DELL’ADENOCARCINOMA POLMONARE IN II LINEA: NIVOLUMAB VS PEMBROLIZUMAB 118
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 117
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 117
90K (Mac-2 BP) in human milk 116
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 115
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 114
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 113
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 112
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 109
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 109
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 109
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 108
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 107
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 106
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 106
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 105
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 105
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 104
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 104
Surgical treatment of adrenal metastases from non small cell lung cancer 103
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 103
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 102
DNA ploidy and S-phase fraction in pulmonary carcinoids. 102
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 102
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 102
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 102
Chemotherapy preoperative for the management of breast cancer locally advanced 101
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 101
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 101
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 100
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 100
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 100
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 100
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 99
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 98
Tyrosine kinase inhibitors 98
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 97
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 97
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 96
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 96
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 96
Principali effetti collaterali delle terapie mediche 96
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer 96
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 95
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 95
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 95
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 95
Unknown primary tumors 94
A Flow cytometric study of early gastric cancer 93
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 93
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 93
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 92
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 92
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 91
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 91
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 90
Tumor-derived microvesicles: The metastasomes. 90
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 90
Prognostic value of 90K protein in HIV infection 89
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 89
Interleukin-30 Promotes Breast Cancer Growth and Progression 89
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 89
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 89
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 89
Prognostic value of a novel circulating serum 90K antigen in breast cancer 88
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 88
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 88
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 88
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 88
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 87
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies 87
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 87
La stimolazione dinamica con IFN-α per la diagnosi precoce di ripresa di malattia in pazienti NED 86
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 86
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. 86
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 86
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 86
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 85
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 85
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 85
Immunological effects of alternative weekly interferon–alpha–2b and low dose interleukin–2 in patients with cancer 85
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. 85
DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. 85
Circadian timing of chemotherapeutic agents:a phase II study of 5-fluoro-2-deoxyuridine in gastrointestinal cancer and renal cell carcinoma 84
Combinations of biological response modifiers: rationale and clinical responses. 84
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 84
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 83
Neoadjuvant Chemotherapy for Surgically Staged IIIA N2 Non-Small Cell Lung Cancer (NSCLC) in the Elderly 82
Totale 10.002
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.837
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.837
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.228 0 22 278 12 90 287 34 43 97 151 84 130
2021/20221.092 23 33 8 193 114 26 23 69 78 28 131 366
2022/20233.858 310 474 269 470 390 717 200 328 445 37 133 85
2023/20241.589 130 55 119 47 126 552 286 49 25 49 16 135
2024/20253.673 202 692 532 115 86 173 137 218 355 188 418 557
2025/2026742 674 68 0 0 0 0 0 0 0 0 0 0
Totale 18.646